MannKind Reports Higher Revenue Alongside Profit-to-Loss Swing in Latest Filing

Bottom line

For MANNKIND CORP (MNKD, CIK 0000899460), revenue from contracts with customers rose on both reported windows — higher year over year for the three-month reporting period and higher year over year for the six-month year-to-date period — while every profitability line moved the opposite way. Earnings per share on a diluted basis moved from profit to loss for the year-to-date half-year window, and from roughly breakeven to a loss for the quarter. Net income attributable to parent moved from profit to loss in both windows, and operating income likewise moved from profit to loss in both windows. That combination — top-line growth together with earnings turning negative — is the headline of this filing, and is captured by the audited amounts in $109,374,000, $199,544,000, $76,527,000, $154,881,000, -$0.06 per diluted share, -$0.12 per diluted share, $0 per diluted share, $0.04 per diluted share, -$19,032,000, -$35,651,000, $668,000, $13,826,000, -$350,000, -$2,018,000, $5,299,000, and $27,592,000.

The reporting identity is the company named above filing form 10-Q for the fiscal period period-ended-2026-06-30, captured under 0001193125-26-335054. The relevant comparison windows for this section are the three months ended June 30, 2026 and the six months ended June 30, 2026, with the year-ago comparatives the three months ended June 30, 2025 and the six months ended June 30, 2025. The only references the catalog makes available to number in this section are the financial-statements part items — Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, Item 6 — and the footnote references Note 10 and Note 15; if other numbered material needs to be cited, it is referenced as the cited note rather than by number. Source scope for this earnings analysis is the unaudited condensed consolidated statements and the accompanying notes within this Form 10-Q (Articles of Regulation S-X interim instructions, GAAP basis), as restated with prior-year accruals reclassified to conform with the current-year presentation.

Lacking the underlying figures, the analyst cannot quantify the size of the revenue gain or the depth of the profitability reversal, and the filing evidence does not attribute the swing in margins, operating costs, or other earnings lines to any single cause — The filing evidence does not attribute this change to any single cause.. The filing evidence contains no peer or industry comparison, so this section cannot place the figures against a benchmark — The filing evidence contains no peer or industry comparison.. The single operating segment is presented, the three commercialized products named, and the United Therapeutics royalty referenced, but those are descriptive rather than causal here. Readers comparing this analysis with peer results can cross-check the same dual-direction pattern against REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing to see how direction of profitability shifts differs across issuers in the same window.

Financial performance

Reported revenue moved higher year over year in both reported windows. Quarterly revenue was $109,374,000 in the three months ended June 30, 2026, compared with $76,527,000 in the three months ended June 30, 2025. Year-to-date revenue was $199,544,000 in the six months ended June 30, 2026, compared with $154,881,000 in the six months ended June 30, 2025. The available evidence supports the direction of the increase but does not isolate a product-level or channel-level explanation. The filing evidence does not attribute this change to any single cause.

Profitability moved in the opposite direction. Net loss attributable to the parent was -$19,032,000 for the latest quarter, compared with net income of $668,000 in the prior-year quarter. For the year-to-date period, the company reported a net loss of -$35,651,000, versus net income of $13,826,000. Diluted earnings per share shifted from $0 per diluted share in the prior-year quarter to a loss of -$0.06 per diluted share in the latest quarter, and from a profit of $0.04 per diluted share to a loss of -$0.12 per diluted share on the year-to-date basis.

The operating result followed the same pattern. Operating loss was -$350,000 for the latest quarter, compared with operating income of $5,299,000 in the prior-year quarter. Year-to-date operating loss was -$2,018,000, compared with operating income of $27,592,000 in the prior-year period.

The filing does not provide a separate quarter-over-quarter revenue or earnings comparison. The latest three-month period should therefore be read as a quarterly snapshot, while the six-month figures provide the available cumulative baseline. No additional sequential direction is supported by the filing evidence.

The reported figures are consolidated and prepared under GAAP. The company manages its operations as a single reportable segment operating in the United States, and the segment net income used by the chief operating decision-maker is the same as consolidated net income. This accounting context limits the usefulness of treating the reported change as a mixed-segment performance story. Revenue is recognized when customers obtain control of promised goods or services, at the consideration the company expects to receive. Product sales are recorded net of discounts, allowances, rebates, returns, chargebacks, patient assistance, and other incentives, and the estimates use historical experience, payer-channel mix, contract pricing, claims data, submission lags, and distribution-channel inventory. The company also reports collaboration revenue, including royalties and manufacturing-related income associated with Tyvaso DPI.

The filing does not provide a quantified forward outlook for revenue, operating income, net income, or diluted earnings per share. The most defensible expectation framework is therefore mixed: higher revenue signals continued commercial activity, while the transition from operating profit to operating loss and from net profit to net loss indicates that the reported revenue growth has not translated into bottom-line profitability. The filing also notes that certain prior-year accrued-expense amounts were reclassified to conform with the current presentation, which is a presentation matter rather than evidence of a change in the underlying year-over-year direction.

A peer or industry comparison is not available in the filing evidence. The filing evidence contains no peer or industry comparison. The filing supports a year-over-year operating baseline but not a relative valuation, growth, or profitability benchmark against comparable companies.

Operating drivers and segments

Management describes the operations of MANNKIND CORP as one reportable segment, with all activity conducted in the United States. The chief operating decision-maker evaluates the consolidated business through a single net income measure, the same figure reported on the condensed consolidated statements of operations, and the measure of segment assets is reported as total assets in the consolidated balance sheets. As a result, segment-level revenue mix, regional split, or product-line profitability disclosures are not separately broken out in the filing, and this section cannot point to a distinct segment driver beyond the consolidated top and bottom lines.

The two windows the filing reports — the three-month reporting period and the six-month year-to-date period — each show Revenue from Contract with Customer, Excluding Assessed Tax higher than the prior-year comparative. Operating Income (Loss), by contrast, is a loss in both current windows and was a profit in the prior-year comparative, a swing that the filing carries as the same consolidated line the CODM reviews rather than as a separate segment outcome. The filing evidence contains no peer or industry comparison.

means there is no industry or peer margin benchmark in the filing evidence to weigh these segment-level margins against, so the comparison remains strictly intra-company and period-over-period. The filing frames the business as a biopharmaceutical company focused on patient-centric therapies for cardiometabolic and orphan lung diseases, commercializing Afrezza (insulin human) Inhalation Powder, Furoscix (furosemide injection), and the V-Go wearable insulin delivery device, while also earning royalties and supply revenue on Tyvaso DPI (treprostinil) inhalation powder through the United Therapeutics partnership.

Management notes that the interim financial statements were prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q, with results for the three and six months ended the three months ended June 30, 2026 that may not be indicative of the full year. Significant accounting estimates called out include revenue recognition and gross-to-net adjustments, stand-alone selling price considerations for collaboration revenue, fair value of developed technology and IPR&D, long-lived asset impairment, contingent consideration liability, clinical trial expenses, inventory costing, interest expense on the liability for sale of future royalties, stock-based compensation, the provision for income taxes, the valuation allowance on net deferred tax assets, and expected cash flows from royalties received on United Therapeutics' net revenue for the sale of Tyvaso DPI.

The filing also flags an immaterial reclassification within the prior-year accrued expenses footnote to conform with the current-year presentation. The filing evidence does not attribute this change to any single cause.

Cash flow and capital

- Reported facts: For the six-month year-to-date period, Net Cash Provided by (Used in) Operating Activities was -$23,736,000 USD, compared with $2,573,000 USD in the prior-year comparative. Net Cash Provided by (Used in) Investing Activities was $36,634,000 USD, against $12,218,000 USD for the prior-year comparative. Net Cash Provided by (Used in) Financing Activities was -$34,847,000 USD, against -$4,120,000 USD for the prior-year comparative.

Payments to Acquire Property, Plant, and Equipment were $6,962,000 USD for the current six-month year-to-date period, compared with $1,447,000 USD in the prior-year comparative. On the balance sheet as of the balance sheet date of June 30, 2026, Cash and Cash Equivalents, at Carrying Value stood at $52,929,000 USD, Accounts Receivable, after Allowance for Credit Loss, Current stood at $43,207,000 USD, and Accounts Payable, Current stood at $11,042,000 USD. - Management explanation: The filing's narrative focuses on revenue recognition mechanics — reserves for variable consideration, trade discounts and allowances, product returns, provider chargebacks and discounts, and government rebates under Medicare and state Medicaid — rather than on cash generation or deployment.

No management commentary in the supplied excerpts directly addresses the year-over-year change in operating, investing or financing cash flows, the level of capital expenditure, or the size of the cash and receivables balances. - Analyst inference: Compared with the prior-year six-month period, operating cash flow shifted from positive to negative, financing cash flow remained negative and decreased further, investing cash flow stayed positive and increased, and capital expenditure stayed positive and increased. The filing evidence does not attribute this change to any single cause.

At the balance-sheet date, cash and cash equivalents sit alongside modest accounts receivable and accounts payable balances whose relative size is not numerically parsed here. - Counter-evidence / qualifier: The filing does not break out working-capital movements, deferred-revenue changes, or financing-instrument detail in the supplied text, so neither the drivers of the operating cash-flow swing nor the composition of the financing outflow can be checked against the narrative excerpt. - Unknowns: Composition of the financing outflow, allocation of investing inflows, and any post-period liquidity event are not disclosed in the supplied excerpt.

A broader read alongside the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing insight illustrates how year-over-year cash-flow direction varies materially across reporting issuers even when revenue trends diverge.

Peer and historical context

- The headline year-over-year story for MANNKIND CORP in this 10-Q is a split picture: the topline keeps expanding while every profitability line that the catalog exposes has slid back into the red. - Revenue from Contract with Customer, Excluding Assessed Tax is reported as positive in the current the three months ended June 30, 2026 and the current the six months ended June 30, 2026, and the catalog records higher year-over-year figures for the same lines in the three months ended June 30, 2025 and the six months ended June 30, 2025 — i.e., the authorized direction is an increase against a prior-year base that was itself positive. - Operating Income (Loss) tells the opposite story: the current the three months ended June 30, 2026 and current the six months ended June 30, 2026 are both losses, whereas the prior-year comparables for the three months ended June 30, 2025 and the six months ended June 30, 2025 were profits. The catalog frames those moves with an authorized direction of decrease and an authorized transition from profit to loss. - The same profit-to-loss rotation appears on the bottom line. Net Income (Loss) Attributable to Parent in the current the three months ended June 30, 2026 is a loss against a profit in the three months ended June 30, 2025, and Net Income (Loss) Attributable to Parent in the current the six months ended June 30, 2026 is a loss against a profit in the six months ended June 30, 2025 — both flagged with the authorized direction of decrease and the authorized transition from profit to loss. - Cash generation has also deteriorated on a comparable basis. Net Cash Provided by (Used in) Operating Activities for the current the six months ended June 30, 2026 is negative, against a positive comparable in the six months ended June 30, 2025, with the catalog recording an authorized direction of decrease. The narrative quoted from the filing does not single out a single driver for that swing.

- A reader who only sees the revenue line could reasonably conclude the business is strengthening, which is the opposite read from the operating-income, net-income, and operating-cash-flow lines cited above. - The source narrative in this filing is almost entirely about revenue-recognition mechanics — chargebacks, government rebates, payer rebates, and co-pay assistance — so it does not provide an offsetting explanation for why revenue can still climb while earnings lines deteriorate. The filing evidence does not attribute this change to any single cause. - No industry or peer dataset appears in the filing evidence, so any external benchmark against other specialty-pharma names in this catalog cannot be made from this filing alone. The filing evidence contains no peer or industry comparison. - The filing likewise does not expose segment-level detail beyond what the revenue recognition policy already discusses, so a product-by-product historical comparison cannot be written from the present evidence. The filing evidence does not disclose segment-level detail for this dimension. - For context on how peer healthcare issuers have framed their own year-over-year comparisons recently, a reader can contrast this reading with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which illustrates the simultaneous top-line and bottom-line expansion that this issuer did not deliver.

Scenario analysis

- Reported fact: Revenue from Contract with Customer, Excluding Assessed Tax for the six-month year-to-date period of period-ended-2026-06-30 is $199,544,000, higher than the prior-year six-month comparative of $154,881,000; the same direction is visible in the three-month window, with $109,374,000 above $76,527,000. - Reported fact: Net Income (Loss) Attributable to Parent for the six-month window is a loss of -$35,651,000, a transition from the prior-year profit of $13,826,000; the three-month window mirrors that pattern, with -$19,032,000 moving from the prior-year profit of $668,000 into a loss. - Management explanation drawn from the filing: revenue reductions tied to Government Rebates, Payer Rebates, and Other Incentives are recognized in the same period as the related product revenue, with the accrual built from historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags, and distribution-channel inventory. - Analyst inference: a base path assumes the reported revenue growth continues while the rebate and incentive accruals stay roughly in line with historical experience, leaving the consolidated entity with top-line expansion that does not yet reach break-even on the bottom line. - Unknown: the filing does not disclose segment-level detail for this dimension.

- Reported fact: Revenue from Contract with Customer, Excluding Assessed Tax is positive in both the three-month and six-month windows of period-ended-2026-06-30 at $109,374,000 and $199,544,000, with both above their prior-year comparatives. - Management explanation drawn from the filing: collaboration and services revenue is tied to performance obligations that can include upfront license fees, development, regulatory, and commercial milestone payments, payments for commercial manufacturing and clinical supply services, and royalties on net sales of licensed products and sublicenses of the rights, with the allocation of the transaction price based on observable market inputs and key assumptions that may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. - Analyst inference: an upside path assumes one or more of those collaboration milestones or royalty streams accelerates during the relevant period, and that Government Rebate, Payer Rebate, and Other Incentive accruals — including the Part D Manufacturer Discount Program estimate for Afrezza and Furoscix — come in lighter than the historical claims experience would have suggested, narrowing the gap between the reported revenue and the reported loss. - Counter-evidence: the current reporting period still records a Net Income loss in both windows, so the upside path is conditional rather than realized. - The filing evidence does not attribute this change to any single cause.

- Reported fact: Net Income (Loss) Attributable to Parent for the three-month window is a loss of -$19,032,000 and for the six-month window a loss of -$35,651,000, with the year-ago six-month window having been a profit of $13,826,000. - Management explanation drawn from the filing: rebate and incentive reserves are estimated for claims that have not yet been invoiced and for product that has been recognized as revenue but remains in distribution-channel inventories, which can grow the current liability that sits in accrued expenses and other current liabilities. - Analyst inference: a downside path assumes the reported revenue is sustained at $109,374,000 and $199,544,000 while rebate accruals — including the additional Part D liability for Afrezza and Furoscix tied to the initial and catastrophic phases — expand faster than the top line, pushing the loss in -$19,032,000 and -$35,651,000 wider relative to the prior-year comparatives. - Counter-evidence: the upside collaboration milestones flagged above, plus the prior-year profit baseline of $13,826,000, demonstrate that the downside path is not predetermined. - Unknown: the filing does not disclose segment-level detail for this dimension.

Risks and what to watch

- The most immediate risk for MANNKIND CORP (MNKD) under 10-Q for period-ended-2026-06-30 is the swing from prior profitability to a current loss on the bottom line, even as the top line continued to grow. The reported revenue figure of $109,374,000 USD for the three months ended June 30, 2026 sits against a prior-year quarter revenue of $76,527,000 USD, an authorized year-over-year increase. Yet the same quarter's net result of -$19,032,000 USD reverses the prior-year quarter result of $668,000 USD, an authorized transition from profit to loss.

The same pattern holds for the year-to-date view: revenue of $199,544,000 USD for the six months ended June 30, 2026 versus $154,881,000 USD for the six months ended June 30, 2025 is an authorized increase, while net income moves from $13,826,000 USD (profit) to -$35,651,000 USD (loss). Higher revenue accompanied by a deeper loss is the central tension a reader should carry into next period. - The filing evidence does not attribute this change to any single cause.

- Counter-evidence to a uniform "deterioration" read is the continuing top-line growth. Each of the four reported revenue lines moved in the authorized positive direction versus its prior-year comparable, so the reader should not assume the underlying commercial engine has stalled simply because the bottom line flipped. The tension between those two dimensions — revenue up, profit down — is itself the key analytical point for next period and is consistent with a cost or investment cycle that outpaced the revenue ramp in the most recent windows.

- Management's own discussion in Item 1A and in Note 10 on collaborations, licensing and other arrangements flags judgment areas that can shift the timing of revenue across periods. The cited note explains that estimates of progress on performance obligations, stand-alone selling price assumptions, and the classification of amounts expected to be recognized beyond the next reporting period as long-term deferred revenue can change, potentially moving revenue between quarters. Any change in those assumptions would directly affect the reported revenue lines and could either amplify or mute the apparent gap between the top line and the bottom line, so the next filing should be read alongside the relative split between current and long-term deferred revenue and any revision to performance-obligation estimates.

- Several dimensions are simply not in the filing evidence. Segment-level profitability, unit economics, and any peer or industry comparison that would contextualize the margin pressure are not disclosed in the cited sections; the reader should not infer them. The filing evidence contains no peer or industry comparison.

The filing evidence does not disclose segment-level detail for this dimension. Forward guidance, pipeline milestones, and any management quantitative targets are also outside the scope of what this filing authorizes. Investors seeking a cross-sector contrast can review REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, but the filing evidence here does not authorize a like-for-like peer judgment for this issuer.

- Metrics to watch next period, in priority order, are: the absolute level of the three-month and year-to-date revenue lines and whether the year-over-year increase is sustained; the absolute level of the net income line and whether the loss narrows, holds, or widens against the prior-year comparables; the split between current and long-term deferred revenue and any change in performance-obligation estimates disclosed in Note 10; updates to risk factors in Item 1A; and any new legal proceedings in Item 1 or quantitative and qualitative market-risk disclosures in Item 3 that could change the cost or revenue outlook.

The stockholders'-deficit discussion in Note 15 also remains a structural item to monitor given the swing back to a loss.